Organogenesis HoldingsFRA:2PQ 66 Shareholder Yield % is 5.92% as of Mar. 2026. GuruFocus rates FRA:2PQ with a GF Score™ of 66/100 and a GF Value™ of €2.71 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 970 Drug Manufacturers companies, Organogenesis Holdings ranks better than 84.43% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Organogenesis Holdings's Shareholder Yield % was 5.92%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Organogenesis Holdings Shareholder Yield % Related Terms
Organogenesis Holdings Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Organogenesis Holdings's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2PQ vs TKNO, AKBA, SIGA: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Organogenesis Holdings (FRA:2PQ) has a Shareholder Yield % of 5.92% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Organogenesis Holdings and its competitors. According to the industry distribution chart, Organogenesis Holdings ranks #151 out of 970 companies in the Drug Manufacturers industry, placing it in the top 15.6%.
Is Organogenesis Holdings' Shareholder Yield % too high?
Organogenesis Holdings' current Shareholder Yield % is 5.92%. The Drug Manufacturers industry median Shareholder Yield % is 0.30. Organogenesis Holdings' value of 5.92% is 1873.3% above this industry median. Based on the distribution chart, Organogenesis Holdings ranks #151 out of 970 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organogenesis Holdings has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Shareholder Yield % compare to TKNO and AKBA?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #151 out of 970 companies for Shareholder Yield %. This places Organogenesis Holdings in the top 16% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 0.30. Organogenesis Holdings' value of 5.92% is 1873.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.30, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current Shareholder Yield % of 5.92% is 1873.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Organogenesis Holdings and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current Shareholder Yield % is 5.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (FRA:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.71, compared to a current price of €2.06 — trading 24% below its estimated fair value. The current Shareholder Yield % is 5.92% and 1873.3% above the Drug Manufacturers industry median of 0.30. Organogenesis Holdings' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Organogenesis Holdings (FRA:2PQ), the current Shareholder Yield % is 5.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (FRA:2PQ) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of €2.06 is trading 24% below its estimated GF Value™ of €2.71.
GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.
Key valuation signals for FRA:2PQ:
Shareholder Yield %: 5.92%
GF Value™: €2.71 vs. price of €2.06 (24% below fair value)
Industry Position: 1873.3% above the Drug Manufacturers median (#151 of 970)
No single metric tells the full story. See the FRA:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
66GF Score
Get the complete analysis for FRA:2PQ
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2PQ has been successfully added to your 
